Skip to main content
Equibles

BARCLAYS PLC

Position in GILD — Gilead Sciences, Inc.

CIK 312069 LONDON, X0
Back to GILD Full portfolio

Position in GILD

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$736,179,654
-$382,654,727 QoQ
Shares Held
5,282,196
-42.1% QoQ
Ownership
0.425%
of shares outstanding
% of Portfolio
0.33%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 99.92238076739297.ToString("F0")% Shared 0.ToString("F0")% None 0.0776192326070445.ToString("F0")%

Common Shares in GILD Over Time

Shares Held

Position Value (USD)

Derivatives in GILD

reported options exposure · as of Mar 31, 2026
CallValue
$41,880,685
CallShares
300,500
PutValue
$35,413,917
PutShares
254,100

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Mar 31, 2026

BARCLAYS PLC holds $8,691,009,698 across 16 Drug Manufacturers - General names. GILD ranks #6 (8.5% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 JNJ
Johnson & Johnson
 6,786,107 $1,658,795,994
2 LLY
ELI LILLY & Co
 1,563,625 $1,438,175,365
3 ABBV
AbbVie Inc.
 5,571,610 $1,211,769,456
4 AZN
Astrazeneca PLC
 5,491,992 $1,083,130,660
5 MRK
Merck & Co., Inc.
 7,557,518 $909,093,835
6 GILD
Gilead Sciences, Inc.
This page 		5,282,196 $736,179,654
7 AMGN
Amgen Inc
 1,529,613 $538,194,332
8 PFE
Pfizer Inc
 14,689,187 $412,472,368

All Filings in GILD

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $35,413,917 254,100
2026-03-31 $736,179,654 5,282,196
2026-03-31 $41,880,685 300,500
2025-12-31 $1,118,834,381 9,115,483
2025-12-31 $34,870,434 284,100
2025-12-31 $30,746,370 250,500
2025-09-30 $574,219,428 5,173,148
2025-09-30 $31,535,100 284,100
2025-09-30 $27,805,500 250,500
2025-06-30 $36,975,145 333,500
2025-06-30 $675,938,354 6,096,675
2025-06-30 $27,772,935 250,500
2025-03-31 $33,592,590 299,800
2025-03-31 $627,957,891 5,604,265
2025-03-31 $14,857,830 132,600
2024-12-31 $26,888,907 291,100
2024-12-31 $406,436,032 4,400,087
2024-12-31 $11,786,412 127,600
2024-09-30 $10,697,984 127,600
2024-09-30 $354,542,423 4,228,798
2024-09-30 $9,608,064 114,600
2024-06-30 $16,075,323 234,300
2024-06-30 $319,475,052 4,656,392
2024-03-31 $9,258,800 126,400
2024-03-31 $498,641,975 6,807,399
2024-03-31 $4,634,381 63,268
2023-12-31 $16,364,020 202,000
2023-12-31 $8,376,434 103,400
2023-12-31 $460,134,367 5,679,970
2023-09-30 $286,277,317 3,820,087
2023-09-30 $3,956,832 52,800
2023-09-30 $24,775,164 330,600
2023-06-30 $511,969,072 6,642,910
2023-06-30 $13,441,008 174,400
2023-06-30 $34,542,774 448,200
2023-03-31 $3,916,184 47,200
2023-03-31 $374,752,919 4,516,728
2023-03-31 $20,543,372 247,600
2022-12-31 $514,024,125 5,987,468
2022-12-31 $18,062,840 210,400
2022-09-30 $114,057,341 1,848,879
2022-06-30 $132,401,159 2,142,067
2022-03-31 $173,601,131 2,920,120
2021-12-31 $72,711,654 1,001,400
2021-12-31 $389,234,471 5,360,618
2021-12-31 $19,394,131 267,100
2021-09-30 $215,689,672 3,087,898
2021-09-30 $12,125,960 173,600
2021-09-30 $35,972,750 515,000
2021-06-30 $185,324,361 2,691,321

Report a Problem

Category
Description
Email (optional, for follow-up)